NT Pharma’s lack of cornerstones no cause for concern
China NT Pharma Group launched its initial public offering on Monday in a deal that could raise up to HK$2.142bn (275m). Bankers on and away from the deal are not concerned by the deal’s lack of cornerstone investment due to the popularity of the healthcare sector in Hong Kong and China.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts